Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERS	SHIP
---	------

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Axon Steven						2. Issuer Name and Ticker or Trading Symbol Apellis Pharmaceuticals, Inc. [APLS]								heck all D	ationship of Reporti k all applicable) Director Officer (give title			son(s) to Issi 10% Ow Other (s	wner
(Last) (First) (Middle) C/O APELLIS PHARMACEUTICALS, INC 6400 WESTWIND WAY, SUITE A						3. Date of Earliest Transaction (Month/Day/Year) 02/16/2018									elow)		iness	below)	
(Street) CRESTWOOD KY 40014 (City) (State) (Zip)					-	4. If Amendment, Date of Original Filed (Month/Day/Year) tive Securities Acquired, Disposed of, or Benefic								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				saction	ı	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.		4. Securities Acquired (A)		red (A) or	or 5. Amou Securiti Benefic Owned		nt of es ally Following	Form (D) o	n: Direct or Indirect 1 ostr. 4) (7. Nature of Indirect Beneficial Ownership	
Common Stock (02/2	0/201	18			Code	v	Amount 38,61	(D)		Tra (In:	Reported Transaction(s) (Instr. 3 and 4)		D		(Instr. 4)
			Table II - I								osed of, converti			y Own	ed				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	4. Transaction Code (Instr. 8)				6. Date E Expiratio (Month/D	n Date	•	of Securities		Deriva Secur	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$14.95	02/16/2018			A		60,000		(1)	(02/15/2028	Common Stock	60,000	\$0.	00	60,000	0	D	
Stock Option (right to	\$2.59	02/20/2018			M		38,610		(2)		05/17/2027	Common Stock	38,610	\$0.	00	359,88	39	D	

Explanation of Responses:

- 1. This option was granted on February 16, 2018 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.
- 2. This option was granted on May 18, 2017 and has vested as to 25% of the shares underlying the options on January 1, 2018, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through January 1, 2021, subject to continued service.

Remarks:

/s/ David Watson, attorney-infact for Steven Axon

02/20/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.